SCHEMBL1369200

SCHEMBL1369200

N#CCc1cnc(Cc2ccc(C(=O)NCCc3ccc(Cl)cc3)cc2)c2ccccc12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 4/20 0.57
RAB9A P51151 5/20 0.48
NPC1 O15118 4/20 0.48
MAPT P10636 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
GAA P10253 2/20 0.48
CYP1A2 P05177 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C19 P33261 1/20 0.48
GFER P55789 1/20 0.48
MCHR1 Q99705 1/20 0.45
LMNA P02545 2/20 0.45
TP53 P04637 1/20 0.45
POLB P06746 1/20 0.45
RXFP1 Q9HBX9 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
SNCA P37840 4/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
SIRT1 Q96EB6 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1370676 0.86 PTGDR2 (0.75) PTGDR2RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL1368383 0.85 PTGDR2 (0.63) PTGDR2RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL1368120 0.85 PTGDR2 (0.63) PTGDR2RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL14859000 0.85 PTGDR2 (0.63) PTGDR2RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL14871008 0.84 PTGDR2 (0.61) PTGDR2RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL14859558 0.82 PTGDR2 (0.57) PTGDR2RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL14860438 0.82 PTGDR2 (0.57) PTGDR2RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL1369213 0.81 PTGDR2 (0.53) PTGDR2RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL1366799 0.80 PTGDR2 (0.66) PTGDR2RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL1369034 0.79 PTGDR2 (0.52) PTGDR2RAB9ANPC1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102264704-B Isoquinoline derivative TAISHO PHARMACEUTICAL CO LTD 2014-06-04 CN disclosed
US-8461329-B2 Isoquinoline derivative TAISHO PHARMACEUTICAL CO., LTD. (JP) 2013-06-11 US disclosed
CN-102264704-A Isoquinoline derivative 2011-11-30 CN disclosed
US-20110288293-A1 ISOQUINOLINE DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2011-11-24 US disclosed
EP-2377851-A1 ISOQUINOLINE DERIVATIVE Taisho Pharmaceutical Co., Ltd. (JP) 2011-10-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110288293-A1 ISOQUINOLINE DERIVATIVE HRH1, HRH2, HRH4 PTGDR2 189/4885RAB9A 1548/4885NPC1 161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.